-
Something wrong with this record ?
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
H. Wu, K. Yang, Z. Zhang, ED. Leisten, Z. Li, H. Xie, J. Liu, KA. Smith, Z. Novakova, C. Barinka, W. Tang,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Hep G2 Cells MeSH
- HeLa Cells MeSH
- Histone Deacetylase 6 antagonists & inhibitors metabolism MeSH
- Histone Deacetylase Inhibitors pharmacology therapeutic use MeSH
- Humans MeSH
- MCF-7 Cells MeSH
- Multiple Myeloma drug therapy enzymology MeSH
- Cell Proliferation drug effects physiology MeSH
- Antineoplastic Agents pharmacology therapeutic use MeSH
- Drug Development methods MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90. HDAC6 is involved in multiple disease-relevant pathways. Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand. We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degradation for the antiproliferation of multiple myeloma (MM). This new class of degraders exhibited improved potency and selectivity for the degradation of HDAC6. After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023749
- 003
- CZ-PrNML
- 005
- 20201214131041.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.9b00516 $2 doi
- 035 __
- $a (PubMed)31271281
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Wu, Hao
- 245 10
- $a Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity / $c H. Wu, K. Yang, Z. Zhang, ED. Leisten, Z. Li, H. Xie, J. Liu, KA. Smith, Z. Novakova, C. Barinka, W. Tang,
- 520 9_
- $a Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90. HDAC6 is involved in multiple disease-relevant pathways. Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand. We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degradation for the antiproliferation of multiple myeloma (MM). This new class of degraders exhibited improved potency and selectivity for the degradation of HDAC6. After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.
- 650 _2
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a proliferace buněk $x účinky léků $x fyziologie $7 D049109
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a vyvíjení léků $x metody $7 D000076722
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a histondeacetylasa 6 $x antagonisté a inhibitory $x metabolismus $7 D000073864
- 650 _2
- $a inhibitory histondeacetylas $x farmakologie $x terapeutické užití $7 D056572
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 _2
- $a mnohočetný myelom $x farmakoterapie $x enzymologie $7 D009101
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Yang, Ka
- 700 1_
- $a Zhang, Zhongrui
- 700 1_
- $a Leisten, Eric D
- 700 1_
- $a Li, Ziyuan
- 700 1_
- $a Xie, Haibo
- 700 1_
- $a Liu, Jin
- 700 1_
- $a Smith, Kerry A
- 700 1_
- $a Novakova, Zora $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV , Prumyslova 595 , 252 50 Vestec , Czech Republic.
- 700 1_
- $a Barinka, Cyril $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV , Prumyslova 595 , 252 50 Vestec , Czech Republic.
- 700 1_
- $a Tang, Weiping
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 62, č. 15 (2019), s. 7042-7057
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31271281 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131039 $b ABA008
- 999 __
- $a ok $b bmc $g 1596068 $s 1114425
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 62 $c 15 $d 7042-7057 $e 20190717 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20201125
